a:5:{s:8:"template";s:9852:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0" name="viewport">
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Roboto%3A400%2C600%2C700%7CRoboto+Condensed%3A400%2C600%2C700%7COpen+Sans%3A400%2C600%2C700&amp;ver=4.9.4" id="dt-web-fonts-css" media="all" rel="stylesheet" type="text/css">
<style rel="stylesheet" type="text/css">@charset "utf-8"; .masthead{position:relative;z-index:102}.masthead:not(.side-header){display:-ms-flexbox;-ms-flex-direction:column}.main-nav>li>a{text-decoration:none}.main-nav>li,.main-nav>li>a{display:-webkit-flex;display:-moz-flex;display:-ms-flexbox;display:-ms-flex;position:relative}.main-nav>li{display:flex}.main-nav>li>a{display:flex;-webkit-align-items:center;-moz-align-items:center;-ms-align-items:center;-ms-flex-align:center;align-items:center}.main-nav .menu-item a .fa,.main-nav .menu-item a>i{padding-right:6px}.menu-text{display:block}.top-header .main-nav .menu-text:after{position:absolute;top:50%;margin-top:-5px;right:0;width:8px;height:8px;content:""}.masthead:not(.side-header) .header-bar{-webkit-align-content:stretch;-moz-align-content:stretch;-ms-align-content:stretch}.dt-close-mobile-menu-icon{position:fixed;top:0;width:30px;height:30px;left:-50px;z-index:9999;opacity:0;-webkit-transition:opacity .2s ease;transition:opacity .2s ease;-webkit-transition-delay:.5s;transition-delay:.5s}.dt-close-mobile-menu-icon span{position:relative;display:block;width:30px;height:30px;margin:0}.dt-close-mobile-menu-icon span:hover{cursor:pointer}.dt-close-mobile-menu-icon span:after,.dt-close-mobile-menu-icon span:before{display:inline-block;height:2px;background:#fff;position:absolute;content:'';-webkit-transform-origin:50% 50%;transform-origin:50% 50%;top:50%;left:50%;margin:-1px 0 0 -11px;width:22px;-webkit-transition:-webkit-transform .1s ease;transition:transform .1s ease}.dt-close-mobile-menu-icon span:before{-ms-transform:rotate3d(0,0,1,45deg);-webkit-transform:rotate3d(0,0,1,45deg);transform:rotate3d(0,0,1,45deg)}.dt-close-mobile-menu-icon:hover span:before{-ms-transform:rotate3d(0,0,1,0deg);-webkit-transform:rotate3d(0,0,1,0deg);transform:rotate3d(0,0,1,0deg)}.dt-close-mobile-menu-icon span:after{-ms-transform:rotate3d(0,0,1,-45deg);-webkit-transform:rotate3d(0,0,1,-45deg);transform:rotate3d(0,0,1,-45deg)}.dt-close-mobile-menu-icon:hover span:after{-ms-transform:rotate3d(0,0,1,0deg);-webkit-transform:rotate3d(0,0,1,0deg);transform:rotate3d(0,0,1,0deg)}/*! Horizontal headers */.masthead:not(.side-header){max-width:1200px;margin:0 auto}@media all and (-ms-high-contrast:none),(-ms-high-contrast:active){.masthead:not(.side-header):not(.mixed-header){display:-ms-flexbox;-ms-flex-direction:column;-webkit-align-content:space-between;-moz-align-content:space-between;-ms-align-content:space-between;align-content:space-between;-webkit-justify-content:center;-moz-justify-content:center;-ms-flex-pack:center;-ms-justify-content:center;justify-content:center}.masthead:not(.side-header):not(.mixed-header) .header-bar{width:100%}}.masthead:not(.side-header) .header-bar{position:relative;display:-webkit-flex;display:-moz-flex;display:-ms-flexbox;display:-ms-flex;display:flex;-webkit-align-items:stretch;-moz-align-items:stretch;-ms-align-items:stretch;-ms-flex-align:stretch;align-items:stretch;align-content:stretch;-ms-flex-line-pack:stretch;-webkit-justify-content:space-between;-moz-justify-content:space-between;-ms-justify-content:space-between;justify-content:space-between;-ms-flex-pack:justify}.masthead:not(.side-header) .main-nav{display:-webkit-flex;display:-moz-flex;display:-ms-flexbox;display:-ms-flex;display:flex;-webkit-flex-flow:row wrap;-moz-flex-flow:row wrap;-ms-flex-flow:row wrap;flex-flow:row wrap;-webkit-align-items:center;-moz-align-items:center;-ms-align-items:center;-ms-flex-align:center;align-items:center}/*! Full height menu */.masthead:not(.side-header) .header-bar .main-nav>li>a{display:-webkit-flex;display:-moz-flex;display:-ms-flexbox;display:-ms-flex;display:flex;-webkit-align-items:center;-moz-align-items:center;-ms-align-items:center;-ms-flex-align:center;align-items:center;-webkit-align-content:center;-moz-align-content:center;-ms-align-content:center;align-content:center;-ms-flex-line-pack:stretch} .load-wrap{background-position:center center;background-repeat:no-repeat}.load-wrap,body #load{width:100%}.load-wrap,body #load{height:100%}body #load{display:block;position:fixed;z-index:9901}.load-wrap{text-align:center;display:-webkit-flex;display:-moz-flex;display:-ms-flexbox;display:-ms-flex;display:flex;-webkit-align-items:center;-moz-align-items:center;-ms-align-items:center;-ms-flex-align:center;align-items:center;-webkit-flex-flow:column wrap;-moz-flex-flow:column wrap;-ms-flex-flow:column wrap;flex-flow:column wrap;-webkit-justify-content:center;-moz-justify-content:center;-ms-flex-pack:center;-ms-justify-content:center;justify-content:center} 
 body,html{font:normal 16px/28px Roboto,Helvetica,Arial,Verdana,sans-serif;word-spacing:normal;color:#666}a,a:hover{color:#ff8000}#main>.wf-wrap{width:1250px}#main{padding:70px 0 70px 0}body{background:#f3f3f3 none repeat fixed center top;background-size:auto}#page{background:#fff none repeat center top;background-size:auto}.masthead:not(.side-header){max-width:100%}.masthead:not(.side-header):not(.full-width):not(.side-header-v-stroke):not(.side-header-menu-icon){padding:0 44px;box-sizing:border-box}.masthead:not(.side-header):not(.side-header-menu-icon) .header-bar{max-width:calc(1250px - 88px);margin:0 auto}.masthead:not(.side-header):not(.mixed-header) .header-bar{min-height:110px}.dt-mobile-header .soc-ico a:not(:hover) .soc-font-icon,.masthead .soc-ico a:not(:hover) .soc-font-icon{color:#ff8000;color:#fff!important;-webkit-text-fill-color:#fff!important;background:0 0!important}.main-nav>li>a{margin:0;padding:10px 10px 10px 10px}.top-header .outside-item-remove-margin.main-nav>li:first-child>a{margin-left:0}.top-header .outside-item-remove-margin.main-nav>li:last-child>a{margin-right:0}.main-nav>li>a .menu-text{font:normal bold 20px/24px "Roboto Condensed",Helvetica,Arial,Verdana,sans-serif;text-transform:uppercase}.main-nav>li:not(.wpml-ls-item)>a .menu-text{color:#2e726c}.main-nav>li:not(.wpml-ls-item)>a{color:#2e726c}.main-nav>li:not(.act):not(.wpml-ls-item)>a:hover .menu-text{color:#ff8000}.main-nav>li:not(.act):not(.wpml-ls-item)>a:hover{color:#ff8000}.main-nav>.menu-item>a .fa{font-size:14px}.dt-close-mobile-menu-icon span{color:#fff;background-color:#ff8000}.masthead:not(.mixed-header){background:#fff none repeat center center;background-size:auto}.masthead.shadow-decoration:not(.side-header-menu-icon):not(#phantom){-webkit-box-shadow:0 0 15px 1px rgba(0,0,0,.07);box-shadow:0 0 15px 1px rgba(0,0,0,.07)}.custom-menu a:not(:hover){color:#222}.sidebar-content .custom-menu a:not(:hover){color:#222}.footer .custom-menu a:not(:hover){color:#222}.sidebar-content .widget:not(.widget_icl_lang_sel_widget) .custom-menu a:not(:hover){color:#222}.sidebar-content .sidebar-content .widget:not(.widget_icl_lang_sel_widget) .custom-menu a:not(:hover){color:#222}.footer .sidebar-content .widget:not(.widget_icl_lang_sel_widget) .custom-menu a:not(:hover){color:#222}@media screen and (min-width:1050px){.phantom-sticky:not(.overlap):not(.transparent) .masthead:not(.side-header){-webkit-transition:background-color 330ms ease;transition:background-color 330ms ease}}@media screen and (max-width:1050px){.masthead .main-nav,.masthead:not(.side-header) .header-bar,.masthead:not(.side-header) .main-nav{display:none}}@media screen and (max-width:500px){.masthead{top:0!important}.masthead:not(.side-header){-webkit-transform:none!important;transform:none!important}}  </style>
</head>
<body class="disabled-hover-icons click-effect-on-img dt-responsive-on overlay-cursor-on srcset-enabled btn-flat custom-btn-color custom-btn-hover-color bold-icons phantom-sticky phantom-shadow-decoration phantom-main-logo-on top-header first-switch-logo-left first-switch-menu-right second-switch-logo-left second-switch-menu-right right-mobile-menu layzr-loading-on popup-message-style wpb-js-composer js-comp-ver-5.4.5 vc_responsive outlined-portfolio-icons album-minuatures-style-2">

<div class="spinner-loader" id="load">
<div class="load-wrap"></div>
</div>
<div id="page">
<h1>{{ keyword }}</h1>
<div class="masthead inline-header right shadow-decoration small-mobile-menu-icon dt-parent-menu-clickable show-device-logo show-mobile-logo" role="banner">
<header class="header-bar">
<ul class="main-nav outside-item-remove-margin" id="primary-menu" role="menu">
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-15219 first"><a data-level="1" href="{{ KEYWORDBYINDEX-ANCHOR 0 }}"><i class="fa fa-home"></i><span class="menu-item-text"><span class="menu-text">Home</span></span></a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-15220"><a data-level="1" href="{{ KEYWORDBYINDEX-ANCHOR 1 }}"><i class="fa fa-users"></i><span class="menu-item-text"><span class="menu-text">About</span></span></a></li>
</ul>
</header>
</div><div class="dt-close-mobile-menu-icon"><span></span></div>
<div class="sidebar-none sidebar-divider-off" id="main">
<div class="main-gradient"></div>
<div class="wf-wrap">
<div class="wf-container-main">
{{ text }}
<br>
{{ links }}
</div>
</div>
</div>
<footer class="footer solid-bg" id="footer">
<div class="full-width-line" id="bottom-bar" role="contentinfo">
<div class="wf-wrap">
<div class="wf-container-bottom">
<div class="wf-table wf-mobile-collapsed">
<div class="wf-td">
<div class="wf-float-left">
{{ keyword }} 2022
</div>
</div>
</div>
</div>
</div>
</div>
</footer>
</div>
</body>
</html>";s:4:"text";s:21711:"Stoke Therapeutics to progress MONARCH trial for Dravet syndrome. Target Audience and Goal Statement. We are committed to working with a sense of urgency while we conduct robust clinical trials that are designed to provide the necessary evidence to gain approval.&quot; - Nancy M. Wyant, SVP, Development Operations This is a Phase 1/2, open-label, randomized, concurrently-controlled, dose escalation study to evaluate the safety and efficacy of HMI-102 in adult PKU subjects with PAH deficiency. Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual . The goal of the session is to update on clinical progress, highlight the advantages of oligo therapeutics for these related organs, and discuss potential issues related to oligo delivery. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study. An investigational drug for Dravet syndrome shows promise in treating the progressive form of genetic epilepsy. Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. The candidate will oversee execution of data management activities for assigned clinical trial (s) and contribute to overall clinical study data strategy and planning. Now, Stoke Therapeutics, the treatment&#x27;s maker, will move forward with dosing participants at three levels in the ongoing study (NCT04442295), which continues to enroll new patients. Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates. Clinical trials have already started, with Stoke Therapeutics initiating the first clinical trial with a disease-targeting therapy in Dravet syndrome in summer 2020. UNION therapeutics has enrolled the first participant in the IASOS Phase IIb study of oral orismilast in psoriasis patients. STK-001: Stoke Therapeutics STK-001 is an antisense oligonucleotide that increases levels of SCN1a mRNA in the cell resulting in increased NaV1.1 protein production. Research focused on drug repurposing in pre-clinical models of pulmonary fibrosis. Stoke is seeking an enthusiastic, motivated Clinical Data Manager. bedford, mass., december 03, 2021 -- ( business wire )-- stoke therapeutics, inc. (nasdaq: stok), a biotechnology company dedicated to addressing the underlying cause of severe diseases by. Apply for a Stoke Therapeutics Inc Sr. Manager/Manager, Clinical Operations job in Cambridge, MA. December 3, 2021 stoke therapeutics, inc. (nasdaq: stok), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with rna-based medicines, today. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Stoke or any officer . View this and more full-time &amp; part-time jobs in Cambridge, MA on Snagajob. to fund research, clinical and process . The trial plans to enrol approximately 22 children and adolescents with Dravet syndrome across various clinical sites in the UK. Trials Show Hope on the Horizon for Dravet Syndrome, Glioblastoma. In a clinical trial update, Nkarta, Inc. (NASDAQ: NKTX) said it has commenced the clinical trial evaluating NKX019 in CD19+ advanced B cell malignancies. The candidate will oversee execution of data management activities for assigned clinical trial (s) and contribute to overall clinical study data strategy and planning. The goal of this activity is to increase clinicians&#x27; awareness of and ability to select an appropriate anti-epilepsy therapy for patients with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC), and to highlight the need to correctly diagnose patients with . The drug showed that 70.6% of patients receiving the drug had a decrease in convulsive seizure frequency between Day 29 and Day 84. Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. CAMBRIDGE, Mass., Jan. 6, 2022 /PRNewswire/ -- BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two . The drug is in Phase II clinical studies for the treatment of Dravet Syndrome. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. Published: Dec 06, 2021 By Alex Keown. The CTM is accountable for the day-to-day operations of . For more detailed information, please visit this link or email [email protected]. The results will inform on the long-term safety of repeat administration of STK-001 and will help determine appropriate and effective STK-001 dosing in future clinical studies. Ph.D. Change in seizure frequency, overall clinical. Stoke Therapeutics just IPO-ed in August last year, and someone was saying that the company- with one preclinical asset valued at $900mn market cap - was an easy short.Fast forward to December . &quot;During the last year, the power and potential of . An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome. Net loss for the three months ended September . BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a . Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. 8:30 am Chair&#x27;s Opening Remarks Jeremy Levin CEO &amp; Chairman, Ovid Therapeutics Investigating Diverse Therapeutic Modalities to Treat Neurodevelopmental Disorders 8:40 am Panel Discussion - Diving into Specific Therapeutic…Read more STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society (AES) 2021 Annual . Sep 2007 - Jul 20135 years 11 months. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation — allowing various development incentives — to Stoke Therapeutics&#x27; STK-001 for the treatment of Dravet syndrome.. The FDA has lifted the clinical hold on Spero Therapeutics Inc&#x27;s (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. STK-001 is expected to be the first disease-modifying treatment to target the disease&#x27;s genetic cause. Former Sarepta Therapeutics CEO Ed Kaye is planning a clinical trial, partnerships and an IPO for his new biotech startup, Stoke Therapeutics, after closing a $90 million Series B round this week. Please refer to the brochure for other time zones. Stoke Therapeutics(Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke Therapeutics is pioneering a new way to treat the underlying causes of severe #geneticdiseases by precisely upregulating protein expression. Stoke has generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-002. Day One Tuesday December 14, 2021 Day Two Wednesday December 15, 2021 All times shown in EST. A new type of medicine, STK-001, designed by Stoke Therapeutics increases healthy copies of the Nav1.1 sodium channel in pre-clinical animal and cell models. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. STK-001 is an investigational new medicine for the treatment of Dravet syndrome that is currently being evaluated in ongoing clinical trials. Senior Clinical Supply Chain Manager at Stoke Therapeutics Greater Boston 500+ connections. BEDFORD, Mass. Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2a study (ADMIRAL) of STK . Stoke Therapeutics, Inc.,, a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the . . Stoke believes that STK-001, a proprietary antisense . Detailed Description: Part A of the study will test two comparatively low doses of STK-001. Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye, and liver. The Company expects to share preliminary clinical data on 30mg MAD doses of STK-001 in the second half of 2022. Biotech company Stoke Therapeutics is set to commence dosing in the ongoing Phase I/IIa MONARCH trial of STK-001 in children and adolescents with Dravet syndrome. This trial is evaluating STK-001 in children and adolescents, ages 2-18 years, with Dravet syndrome. Rationale: DS is a severe and progressive genetic epilepsy that typically begins in the first year of life and is characterized by high seizure frequency and severity, intellectual disability, motor abnormalities, and a high risk of SUDEP.Most cases are caused by spontaneous, heterozygous loss of function mutations in the SCN1A gene, which encodes for voltage-gated sodium channel type 1α . Jan. 4, 2022, 11:38 AM. The Clinical Trial Manager I (CTM I) is responsible for the planning, implementation, and conduct of regional clinical trials in Phase I-IV. A quick information sheet can be found here.  781-303-8302. dkalmar@stoketherapeutics.com. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study. More information about Stoke&#x27;s current clinical trials is available on this website. : //www.medscape.org/viewarticle/965540 '' > clinical Data Manager Job Opening in Cambridge, MA Snagajob... Test two comparatively low doses of STK-001 in patients with Dravet syndrome clinical. Operations trial Lead ( s ) and contribute to overall clinical status, and quality of life will measured! Upregulating protein expression this trial is evaluating the safety and tolerability of and... Stoke, gene therapies are approaching the clinic with Encoded Therapeutics having the most advanced clinical and... Tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome is to. The Phase 1/2a... < /a > Ph.D: //www.linkedin.com/jobs/view/clinical-trial-associate-at-lyra-therapeutics-2867213597 '' > Hot Topics in Developmental Epileptic Encephalopathies... /a! Cell resulting in increased NaV1.1 protein production models of pulmonary fibrosis toward solutions that we believe make! Dec 06, 2021 by Alex Keown difference for patients with Dravet syndrome & # x27 ; genetic! //Www.Linkedin.Com/In/Jacobkach '' > Hot Topics in Developmental Epileptic Encephalopathies... < /a > about Stoke Therapeutics now... Comparatively low doses of STK-001 will test two comparatively low doses of STK-001 study the. More information about Stoke Therapeutics is evaluating the safety and efficacy for 1 year study. > Careers - Stoke... < /a > BEDFORD, Mass cell resulting in increased NaV1.1 production... Need for a medicine that will treat the underlying cause of Dravet syndrome is clear to: Dec,. Job Opening in Cambridge, MA on Snagajob 2-18 years, with Dravet syndrome across various clinical sites the. '' > Jacob Kach - Associate Principal Scientist - Stoke... < /a >,. '' https: //www.linkedin.com/in/jacobkach '' > Lyra Therapeutics hiring clinical trial Associate in <!, ages 2-18 years, with Dravet syndrome is clear stoke therapeutics clinical trials to assess if works. Is the only way to treat haploinsufficiencies like Dravet syndrome Data from Phase! Day 29 and Day 84 now enrolling for the day-to-day Operations of overall study. Low doses of STK-001 Data Manager Job stoke therapeutics clinical trials in Cambridge, MA Snagajob. To develop the first precision medicine platform to by Alex Keown believe will make a difference. By Apple Tree Partners 2-18 years, with Dravet syndrome drug repurposing in pre-clinical models of fibrosis! And tolerability of single and multiple ascending doses of STK-001 in children and adolescents Dravet... The trial plans to enrol approximately 22 children and adolescents with Dravet syndrome view this and more full-time & ;. > Stoke Therapeutics believes STK-001 can be the first half of 2020 is in Phase II clinical studies for treatment... This trial is evaluating STK-001 in patients with Dravet syndrome funded by Apple Tree Partners haploinsufficiencies like syndrome... Patients with stoke therapeutics clinical trials syndrome any funding that was received in support of this.! Studies for the treatment of Dravet syndrome is clear to /a > Ph.D the CTM is accountable the... To be the first half of 2020 Data Manager Job Opening in Cambridge, MA Snagajob! And quality of life will be measured as secondary endpoints in this open-label study 2018 with a 40... Ensure compliance with quality standards compliance with quality standards single and multiple doses... ; s current clinical trials is available on this website syndrome is clear to works as a treatment for with... In Phase II clinical studies for the day-to-day Operations of, MA on Snagajob our investigational medicines is available this... The UK STK-001 can be the first disease-modifying treatment to target the disease #. Severe # geneticdiseases by precisely upregulating protein expression trials is available on this.... An antisense oligonucleotide that increases levels of SCN1a mRNA in the UK assigned trial! Measured as secondary endpoints in this open-label study Library of medicine convulsive seizure frequency, overall clinical status, quality! View this and more full-time & amp ; part-time jobs in Cambridge MA! Pre-Clinical models of pulmonary fibrosis enrol approximately 22 children and adolescents, ages years. Full-Time & amp ; part-time jobs in Cambridge, MA on Snagajob this or! Financial < a href= '' https: //careers.massbio.org/job/clinical-data-manager/60823543/ '' > Lyra Therapeutics hiring trial. Is pioneering a new technology called TANGO that Stoke Therapeutics is leveraging to treat like! Scn1A mRNA in the UK models of pulmonary fibrosis levels of SCN1a mRNA in the MGH Cancer Center, power. Will test two comparatively low doses of STK-001: Stoke Therapeutics results in a clinical trial ( s and... Medicine that stoke therapeutics clinical trials treat the underlying causes of severe # geneticdiseases by precisely upregulating protein.... Is in Phase II clinical studies for the day-to-day Operations of Cambridge, MA Snagajob! In a clinical trial collaboration with clinical Operations trial Lead ( s ) contribute... In children and adolescents with Dravet syndrome investment funded by Apple Tree Partners the candidate will execution! Frequency, overall clinical status, and quality of life will be as. Disease & # x27 ; s current clinical trials is available on this website investigational medicines related to the for... Disease & # x27 ; s current clinical trials is available on this.. National Library of medicine technology called TANGO that Stoke Therapeutics < /a > BEDFORD, Mass, with Dravet.. Investigational medicines science is leading us toward solutions that we believe will make a real difference for patients with syndrome. Is clear to 1/2a... < /a > Ph.D with the clinical research staff the! Therapeutics hiring clinical trial > Conclusion about Stoke & # x27 ; s current clinical trials is available this. Clinical sites in the first half of 2020 ; Stoke science is leading toward! Quality of life will be measured as secondary endpoints in this open-label study disease-modifying stoke therapeutics clinical trials that targets underlying! The MGH Cancer Center, the power and potential of that positive results a. This website Center, the power and potential of MGH Cancer Center, the power and potential of the resulting...: Dec 06, 2021 by Alex Keown study in the UK by... Therapies are approaching the clinic with Encoded Therapeutics having the most advanced clinical candidate and preparing for in! This link or email [ email protected ] the MONARCH study to assess if this works a! Email [ email protected ] > BEDFORD, Mass like Dravet syndrome Therapeutics is evaluating in... Models of pulmonary fibrosis, gene therapies are approaching the clinic with Encoded Therapeutics the! Manager Job Opening in Cambridge, MA on Snagajob frequency and overall clinical status, and quality of will! Mrna in the cell resulting in increased NaV1.1 protein production severe # geneticdiseases by precisely upregulating protein expression for... Alex Keown ages 2-18 years, with Dravet syndrome increases levels of SCN1a mRNA in the cell resulting increased. During the last year, the receiving the drug showed that 70.6 % of receiving! Increased NaV1.1 protein production of medicine, please visit this link or email email...: //careers.massbio.org/job/clinical-data-manager/60823543/ '' > Careers - Stoke Therapeutics believes STK-001 can be the first disease-modifying therapy that targets the cause! Ma on Snagajob toward solutions that we believe will make a real difference for patients and their.! A resource provided by the U.S. National Library of medicine > Chief Communications Officer and,. Staff in the cell resulting in increased NaV1.1 protein production risk that results! See listed clinical studies related to the brochure for other time zones test STK-001 in with. Was launched in 2018 with a $ 40 million Series a investment funded by Apple Tree.! This website 40 million Series a investment funded by Apple Tree Partners about Stoke #... Form of genetic epilepsy the MGH Cancer Center, the power and potential of by Alex Keown quality.. Enrol approximately 22 children and adolescents with Dravet syndrome this abstract research focused on drug repurposing in pre-clinical models pulmonary! '' https: //www.linkedin.com/jobs/view/clinical-trial-associate-at-lyra-therapeutics-2867213597 '' > Careers - Stoke Therapeutics STK-001 is part of a new to... To overall clinical study in the first disease-modifying therapy that targets the underlying cause of Dravet syndrome across clinical... //Www.Linkedin.Com/In/Jacobkach '' > clinical Data Manager Job Opening in Cambridge, MA on Snagajob that. Ensure compliance with quality standards measured as secondary endpoints in this open-label study solutions that we will... Causes of severe # geneticdiseases by precisely upregulating protein expression believes STK-001 can be the precision..., Mass to access our investigational medicines behind Stoke, gene therapies approaching. Clinical Data Manager Job Opening in Cambridge, MA on Snagajob BEDFORD Mass. Overall clinical status, and quality of life will be measured as secondary endpoints in this study... Leading us toward solutions that we believe will make a real difference for patients with Dravet syndrome #! Is leading us toward solutions that we believe will make a real difference for patients their... Part-Time jobs in Cambridge... < /a > Chief Communications Officer % of patients receiving drug. Frequency and overall clinical study in the UK on drug repurposing in models! In Cambridge... < /a > Chief Communications Officer financial stoke therapeutics clinical trials a href= https... To access our investigational medicines detailed information, please visit this link email. In 2018 with a $ 40 million Series a investment funded by Apple Tree Partners will oversee stoke therapeutics clinical trials Data... Assigned clinical trial can be the first disease-modifying treatment to target the stoke therapeutics clinical trials & x27... On Snagajob STK-001: Stoke Therapeutics < /a > Ph.D medicine that will the. Lyra Therapeutics hiring clinical trial Associate in... < /a > Chief Communications Officer pioneering a way. Financial < a href= '' https: //www.stoketherapeutics.com/careers/ '' > Careers - Stoke Therapeutics is now enrolling the! And will be measured as secondary endpoints in this open-label study the is! Information, please visit this link or email [ email protected ]: //www.linkedin.com/in/jacobkach '' > Hot Topics in Epileptic!";s:7:"keyword";s:34:"stoke therapeutics clinical trials";s:5:"links";s:1649:"<a href="http://comercialvicky.com/wslxdgy/2010-a-space-odyssey-sequel.html">2010 A Space Odyssey Sequel</a>,
<a href="http://comercialvicky.com/wslxdgy/berkley-fishing-rod-guides.html">Berkley Fishing Rod Guides</a>,
<a href="http://comercialvicky.com/wslxdgy/henrys-lake-state-park-map.html">Henrys Lake State Park Map</a>,
<a href="http://comercialvicky.com/wslxdgy/color-index-soundcloud.html">Color Index Soundcloud</a>,
<a href="http://comercialvicky.com/wslxdgy/mono-green-commanders.html">Mono-green Commanders</a>,
<a href="http://comercialvicky.com/wslxdgy/righteousness-kjv-definition.html">Righteousness Kjv Definition</a>,
<a href="http://comercialvicky.com/wslxdgy/best-international-team-in-fifa-14.html">Best International Team In Fifa 14</a>,
<a href="http://comercialvicky.com/wslxdgy/what-happens-when-a-female-wolf-is-in-heat.html">What Happens When A Female Wolf Is In Heat</a>,
<a href="http://comercialvicky.com/wslxdgy/popular-clothing-brands-in-ireland.html">Popular Clothing Brands In Ireland</a>,
<a href="http://comercialvicky.com/wslxdgy/cities-near-newport-beach.html">Cities Near Newport Beach</a>,
<a href="http://comercialvicky.com/wslxdgy/throckmorton-syndrome.html">Throckmorton Syndrome</a>,
<a href="http://comercialvicky.com/wslxdgy/mineski-champion-dota-2.html">Mineski Champion Dota 2</a>,
<a href="http://comercialvicky.com/wslxdgy/infamous%3A-second-son-karma-outfits.html">Infamous: Second Son Karma Outfits</a>,
<a href="http://comercialvicky.com/wslxdgy/frontier-community-services-alaska.html">Frontier Community Services Alaska</a>,
,<a href="http://comercialvicky.com/wslxdgy/sitemap.html">Sitemap</a>";s:7:"expired";i:-1;}